(S)-3-甲基吗啉 | 350595-57-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: (S)-3-甲基吗啉
• 中文别名: S-3-甲基吗啉；3-(S)-3-甲基吗啉
• 英文名称: (S)-3-methylmorpholine
• 英文别名: (3S)-3-methylmorpholine；3-(S)-methylmorpholine
• CAS: 350595-57-2
• 化学式: C₅H₁₁NO
• 分子量: 101.148
• InChiKey: SFWWGMKXCYLZEG-YFKPBYRVSA-N

物化性质

• 沸点：
  137.1±15.0 °C(Predicted)
• 密度：
  0.891±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 海关编码：
  2934999090
• 包装等级：
  II
• 危险类别：
  8,3
• 危险性防范说明：
  P501,P240,P210,P233,P243,P241,P242,P264,P280,P370+P378,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P403+P235,P405
• 危险品运输编号：
  2734
• 危险性描述：
  H314,H226
• 储存条件：
  存放在室温、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-3-Methylmorpholine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-3-Methylmorpholine
CAS number: 350595-57-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11NO
Molecular weight: 101.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

3-(S)-3-甲基吗啉主要用作有机合成与医药化学中间体，可用于药物分子和有机催化反应中手性含氮配体的合成。在有机合成转化过程中，3-(S)-3-甲基吗啉中的氮原子可以与芳基卤化物进行碳氮键偶联反应，在吗啉的氮原子上引入一个芳基基团。

制备

将(S)-5-甲基吗啉-3-酮(237毫克、2.0 mmol)溶解于2毫升四氢呋喃中，然后加入四氢铝锂。将得到的反应混合物在室温下搅拌过夜。反应完成后，缓慢加入冰冷水以分离有机层，并使用无水硫酸钠干燥。过滤除去硫酸钠固体后，将滤液在真空下浓缩即可获得目标产物3-(S)-3-甲基吗啉。

反应信息

• 作为反应物：
  描述：

  (S)-3-甲基吗啉 在 N,N-二异丙基乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.12h， 生成 (S)-2-(2-chloro-7-methyl-6-(3-methylmorpholino)-7H-purin-8-yl)propan-2-ol
  参考文献：
  名称：

  A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors

  摘要：

  A series of N-7-methyl-imidazolopyrimidine inhibitors of the mTOR kinase have been designed and prepared, based on the hypothesis that the N-7-methyl substituent on imidazolopyrimidine would impart selectivity for mTOR over the related PI3K alpha and delta kinases. The corresponding N-Me substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines also show potent mTOR inhibition with selectivity toward both PI3 alpha and delta kinases. The most potent compound synthesized is pyrazolo[4,3-d]pyrimidine 21c. Compound 21c shows a K-i of 2 nM against mTOR inhibition, remarkable selectivity (>2900x) over PI3 kinases, and excellent potency in cell-based assays. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.027
• 作为产物：
  描述：

  2-(2-丙炔氧基)乙胺 在 [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I) 、 甲酸 、 bis(N-2,6-diisoprpylphenylbenzamidato)bis(dimethylamido)titanium (IV) 、 silver trifluoromethanesulfonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 30.0h， 生成 (S)-3-甲基吗啉
  参考文献：
  名称：

  吗啉的催化不对称合成。利用机理见解实现哌嗪的对映选择性合成

  摘要：

  描述了一种有效且实用的催化方法，该方法通过使用氢化胺化反应和不对称转移氢化反应的串联顺序一锅反应，对映选择性合成3-取代的吗啉。从含醚的氨基炔烃底物开始，使用市售的双（氨基甲酸酯）双（酰胺基）Ti催化剂产生环状亚胺，然后使用Noyori–Ikariya催化剂RuCl [（S，S）-Ts-DPEN进行还原]（η 6 - p-cymene），以高收率得到对映体3-取代的吗啉，对映体过量> 95％。宽泛的官能团是可以容忍的。底物范围的研究表明，含醚底物主链中的氧与Ru催化剂的[（S，S）-Ts-DPEN]配体之间的氢键相互作用对于获得高ee至关重要。这种见解导致了预测所观察到的绝对立体化学的机械提议。最重要的是，这种机理上的见解使该策略得以扩展，以包括N作为可以结合到基质中的替代氢键受体。因此，还证明了3-取代的哌嗪的催化，对映选择性合成。

  DOI：

  10.1021/acs.joc.6b01884
• 作为试剂：
  描述：

  4-(2,7-Dichloropyrido[2,3-d]pyrimidin-4-yl)-3-methylmorpholine 、 (S)-3-甲基吗啉 在 (S)-3-甲基吗啉 作用下， 以71的产率得到(3S,3'S)-4,4'-(7-氯吡啶并[2,3-D]嘧啶-2,4-二基)双(3-甲基吗啉)
  参考文献：
  名称：

  WO2007060404A1

  摘要：

  公开号：

文献信息

• CHROMENONE DERIVATIVES
  申请人：BARLAAM Bernard Christophe

  公开号：US20110098271A1

  公开（公告）日：2011-04-28

  The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , n and R 9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  这项发明涉及公式I的香豆素衍生物或其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、n和R9中的每一个具有在描述中定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱的药物的药物中的使用。
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：ONTARIO INST FOR CANCER RES (OICR)

  公开号：WO2017147700A1

  公开（公告）日：2017-09-08

  The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：包括这些化合物的化合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、疾病或症状的药物。
• [EN] 6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS M-TOR INHIBITORS<br/>[FR] DÉRIVÉS DE 6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE EN TANT QU'INHIBITEURS DE M-TOR
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019115640A1

  公开（公告）日：2019-06-20

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

  该发明涉及式(I)的化合物，其中R1、R2、R3、R4、L和A如描述和索赔中所定义，或其药学上可接受的盐，具有mTOR激酶抑制剂活性。该发明还涉及包括式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗中使用式(I)的化合物或其药学上可接受的盐，包括治疗需要mTOR激酶抑制剂活性的疾病或症状，特别是治疗特发性肺纤维化。
• MORPHOLINOPURINE DERIVATIVES
  申请人：Nakayama Kiyoshi

  公开号：US20100130492A1

  公开（公告）日：2010-05-27

  There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , R a , R b , R c , and X each have the same meaning as defined in the specification.

  提供了一种新型化合物，它抑制磷脂酰肌醇3-激酶（PI3K）和/或哺乳动物雷帕霉素靶蛋白（mTOR），并表现出抗肿瘤活性。本发明提供了一种由以下式（1）表示的化合物，具有各种取代基，可抑制PI3K和/或mTOR，并表现出抗肿瘤活性： 其中R1、R2、R3、R4、Ra、Rb、Rc和X的含义与规范中定义的含义相同。